UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
Genomic Profiling to distinguish poorly differentiated neuroendocrine
carcinomas arising in different sites.
Authors*: Emily K. Bergsland, Ritu Roy, Phil Stephens, Jeffrey S. Ross, Mark Bailey, Adam Olshen
Abstract #: 4020
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM
Location: Hall A, Poster Board #12
Poster Session: Gastrointestinal (Noncolorectal) Cancer
Citation: J Clin Oncol 34, 2016 (suppl; abstr 4020)
Bergsland Research Interests: My research is focused on the development and testing of novel, biologically
based therapies for gastrointestinal malignancies, with an emphasis on neuroendocrine tumors (NETs). I am
co-chair of the Neuroendocrine Tumor Task Force of the NCI Gastrointestinal Steering Committee, a NCCN
Neuroendocrine Tumors Guidelines Panel member, Board of Directors member for NANETS, and co-chair
of the 8th edition AJCC Expert Panel on staging for NETs. I am study chair for ALLIANCE A021202 (an
ongoing randomized Phase II trial of pazopanib vs. placebo in patients with progressive carcinoid tumors).
My current research focuses on data from three completed investigator-initiated Phase II clinical trials in NETs
(a. FOLFOX/bevacizumab, b. everolimus plus erlotinib, and c. axitinib), fostering several collaborations with
laboratory-based colleagues, and taking advantage of a fully annotated outcomes database (established in
2010 and encompassing 600+ NET patients treated at UCSF since 2004).
http://cancer.ucsf.edu/gi/emily-bergsland
__________________________________________________________________________
Head and Neck Cancer Updates from the American Society for
Radiation Oncology
Authors*: Sue Sun Yom
Abstract #:
Presentation Date/Time: Saturday, June 4: 8:20 - 8:40 AM
Location: S100bc
Education Session: Best of the Rest: Top Abstracts on Head and Neck Cancer from
the 2015-2016 Oncology Meetings
Citation:
Yom Research Interests: Dr. Yom is an expert in head and neck, thoracic, and skin cancers and conducts
research in quality of life and supportive care, patient-oriented decision making, and combinations of novel
targeted therapies and immunotherapy with radiation therapy. She is the principal investigator of HN002,
a national trial in de-intensified therapy for HPV+ oropharyngeal cancer. She serves on several national
panels developing guidelines for appropriate care of head and neck cancers.
http://profiles.ucsf.edu/sue.yom
*UCSF authors in bold
17